From hyperglycemia to the risk of cardiovascular disease

Reviews in Cardiovascular Medicine

Volumn 7, Issue SUPPL. 2, 2006, Pages

  Leiter, Lawrence A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Diabetes mellitus; Dysglycemia; Hyperglycemia; Metabolic syndrome

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LONG ACTING INSULIN; NATEGLINIDE; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PREDICTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METABOLIC SYNDROME X; PREDIABETIC STATE; RISK ASSESSMENT; RISK FACTORS;

EID: 33846462998     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29:S43-S48.
2. National Diabetes Data Group. Diabetes in America. 2nd Edition. Bethesda, MD: National Diabetes Data Group; 1995.
3. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
4. Knowler WE, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;246:393-403.
5. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420.
6. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Lancet. 1999;354:617-621.
7. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109-2113.
8. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
9. Stratton IM, Adler A, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000:321:405-412.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
11. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
13. Kahn R. The metabolic syndrome (emperor) wears no clothes. Diabetes Care. 2006;29:1693-1696.
14. Grundy SM. Diabetes and coronary risk equivalency. What does it mean? Diabetes Care. 2006; 29:457-460.
15. Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38:52-63.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treat Panel III). JAMA. 2001;285:2486-2497.
17. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;13;110:227-239.
18. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2004; 27(suppl 1):S5-S10.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23: 469-480.
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287:346-359.
21. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
22. Hunt KJ, Resendez RG, Williams K, et al; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110: 1251-1257.
23. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease amount NHANES III participants age 50 and older. Diabetes. 2003;52:1210-1214.
24. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
25. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42-46.
26. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;16;136:575-581.
27. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
28. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54:1-7.